Bedrijfsoverzicht
InflaRx N.V. is a clinical-stage biopharmaceutical enterprise focused on the discovery and development of inhibitors utilizing C5a technology across its operations in Germany and the United States. The company targets a variety of autoimmune and other inflammatory diseases, leveraging C5a as a specific inflammatory mediator for therapeutic intervention within the healthcare sector. Operating specifically within the biotechnology industry, the firm specializes in advancing drug candidates that address complex inflammatory pathways distinct from broader pharmaceutical applications. As of the latest data, the company's market capitalization stands at $72.29M, while its trailing twelve-month revenue is recorded at $29,331 with an employee count of 65 individuals. These valuation and revenue figures indicate that InflaRx N.V. operates as a small-cap entity with limited revenue generation relative to its market capitalization, a common characteristic for clinical-stage biotechnology firms that prioritize research and development expenditures over immediate profit generation, thereby positioning the company in a high-risk, high-potential-growth segment of the biotech landscape.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $29,331, yet posted a net income of $-45,633,780 and an EBITDA of $-48,198,212. The substantial gap between the nominal revenue and the significant negative net income reveals a cost structure dominated by heavy operational and research expenses that far exceed current income generation. Free cash flow for the period was $-14,833,020, indicating that the company is consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity for distribution or expansion. The gross margin is listed at 0.0%, while the operating margin shows an anomalous figure of 37898.3% and the profit margin is 0.0%, suggesting complex accounting treatments or specific adjustments typical of early-stage biotech entities where standard margin calculations may not reflect traditional operational efficiency. Despite these negative earnings metrics, the company holds $46.46M in cash against total debt of $897,916, creating a scenario where cash significantly outweighs liabilities. The debt-to-equity ratio is recorded at 2.16, which, when viewed alongside the cash position, suggests a balance sheet that is leveraged but possesses substantial liquidity buffers to manage obligations. The current ratio stands at 4.13, indicating a robust short-term liquidity position where current assets are more than four times current liabilities. Return on Equity is -88.6% and Return on Assets is -46.0%, metrics that reveal management is currently burning through equity and assets to achieve future clinical milestones rather than generating immediate returns for shareholders.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -1.33, implying that the market prices the stock based on anticipated future profitability rather than current earnings performance. The price-to-book ratio is 1.50, indicating that the market values the company at 1.5 times its book value, which suggests a premium over the net asset value often seen in firms with significant intangible assets or valuable intellectual property portfolios. Alternative valuation metrics such as the price-to-sales ratio of 2464.73 and an EV/EBITDA of -0.56 suggest that traditional multiples are distorted by the lack of profitability, forcing investors to rely on asset-heavy or pipeline-based valuation methods. The 52-week high is $1.94 and the 52-week low is $0.71, meaning the current price context fluctuates within a range where the stock has shown significant volatility but remains below its yearly peak. The beta value is 1.51, which indicates that the stock price is 51% more volatile than the broader market, reflecting the heightened sensitivity of biotechnology equities to sector-specific developments and market sentiment.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet achieved consistent profitability or established a mature revenue stream to calculate standard growth rates. Consequently, earnings growth is not faster than revenue growth because neither metric is currently positive enough to sustain a traditional growth trajectory without significant cash burn. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available earnings and cash reserves directly into research, development, and clinical trials. This reinvestment strategy is typical for clinical-stage biopharmaceutical companies that must allocate capital to advance their lead product candidate, vilobelimab, through regulatory approval processes before generating sustainable income. The overall growth and income profile is characterized by a lack of current income generation and reliance on external capital or existing cash reserves to fuel future expansion and potential commercialization of their C5a inhibitor technology.